Back to mobile site

H.C. Wainwright Reiterates Buy Rating on LENZ Therapeutics Inc (LENZ)

March 25, 2026 6:58 AM EDT Send to a Friend
H.C. Wainwright analyst Matthew Caufield reiterated a Buy rating and $56.00 price target on LENZ Therapeutics Inc (NASDAQ: LENZ).The analyst ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE

Member Login